69.48
+0.93(+1.36%)
Currency In USD
| Previous Close | 68.55 |
| Open | 68.5 |
| Day High | 69.9 |
| Day Low | 67.2 |
| 52-Week High | 86.53 |
| 52-Week Low | 43.7 |
| Volume | 65,435 |
| Average Volume | 50,827 |
| Market Cap | 2.26B |
| PE | -44.83 |
| EPS | -1.55 |
| Moving Average 50 Days | 64.51 |
| Moving Average 200 Days | 62.3 |
| Change | 0.93 |
If you invested $1000 in Belite Bio, Inc (BLTE) since IPO date, it would be worth $6,560.91 as of September 13, 2025 at a share price of $69.48. Whereas If you bought $1000 worth of Belite Bio, Inc (BLTE) shares 2 years ago, it would be worth $2,252.19 as of September 13, 2025 at a share price of $69.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation in Japan for Stargardt diseaseLast subject visit
Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors
GlobeNewswire Inc.
Sep 08, 2025 12:00 PM GMT
Transaction led by RA Capital Management with participation from Eventide Asset Management, Marshall Wace, RTW Investments, Soleus Capital and Vestal Point Capital$125 million financing upfront with up to an additional $150 million tied to exercise o
Belite Bio to Participate in Three Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 27, 2025 12:00 PM GMT
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today